A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection in Patients With Moderate to Severe Atopic Dermatitis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 17
- 主要终点
- Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26
研究概览
简要总结
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
The study will enroll patients with moderate to severe AD to receive the 300 mg treatment. BSI-045B wil be firstly given weekly during Week 1 to Week 4, and then every 2 weeks (Q2W) to Week 24.
详细描述
This study is a Phase 2a, proof-of-concept clinical study designed to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B injection in patients with moderate to severe AD. The study will be unblinded.
Following a loading dose of BSI-045B (300 mg) SC QW for 4 weeks, patients will move to maintanence 300 mg SC Q2W through Week 24. There will be a 12-week Follow-up Period after treatment.
A Safety Steering Committee (SSC) will monitor the study to identify questions concerning safety.
The primary efficacy endpoint is the proportion of patients with ≥EASI75 at Week 26 (2 weeks after last dose at Week 24), compared with baseline (Day1). Additional efficacy outcomes also include other scores on EASI, Investigator's Global Assessment (IGA), Facial IGA, and Peak Pruritus Numerical Rating Scale (PP-NRS). Efficacy assessments will be conducted at Screening, within the first hour prior to dosing on Day 1, at all subsequent visits, and at the time of early withdrawal from the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •The patient has another dermatologic condition that might confound a diagnosis of AD or a treatment assessment.
- •The patient has any clinically significant illness that may affect the safety, increase the risk for seizure or lower the seizure threshold, or potentially confound the study results.
- •The patient has abnormal laboratory values during the Screening Period: ALT and/or AST > 1.5 ULN, total bilirubin ≥ 1.5 mg/dL, estimated glomerular filtration rate (GFR) < 60 mL/min (based on Cockcroft-Gault calculation), hemoglobin≤ 10 g/dL, platelet count ≤ 150 ×103/µL, creatine kinase > 2.5×ULN.
- •The patient has a history of anaphylaxis following biologic therapy.
- •The patient has a history of allergy to corticosteroids, diphenhydramine, hydroxyzine, cetirizine, or fexofenadine.
- •The patient has a history of a clinically significant infection within 4 weeks prior to Screening.
- •The patient has been diagnosed with a helminthic parasitic infection within 6 months prior to Screening.
- •The patient has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to Screening or is unwilling to agree to abstain from alcohol and drugs (including cannabinoids) throughout the study.
- •The patient had a major surgical or major dental procedure within 8 weeks prior to Screening.
- •The patient is pregnant or lactating or intends to become pregnant or donate ova before, during, or within 90 days (~ 5 half-lives) since the last dose of study drug.
- •If male, the patient intends to donate sperm during this study or within 90 days (~ 5 half-lives) since the last dose of study drug.
- •The patient has a history of neurologic abnormalities including abnormal electroencephalography, brain injury including traumatic injury, perinatal cerebropathy, postnatal brain damage, blood-brain barrier abnormality, and cavernous angioma.
- •The patient has a history of cerebral arteriosclerosis.
- •The patient has a history of cancer. Patients with localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix may be included in the study if they have completed curative treatment at least 12 months prior to Screening. Patients with other malignant tumors may be included if they have completed curative treatment at least 5 years prior to the first dose of study drug.
- •The patient has a positive test result for hepatitis B surface antigen (HbsAg), antihepatitis C virus (HCV), a history of active tuberculosis, a positive test result for human immunodeficiency virus (HIV), or a known history of HIV infection at Screening.
- •The patient has poor peripheral venous access.
- •The patient has donated or lost ≥ 450 mL of blood (including plasmapheresis) or had a transfusion of any blood product within 90 days prior to the first dose of study drug.
- •The patient has an abnormal ECG at Screening or on Day -
- •In the case of a corrected QT interval (Fridericia) (QTcF) > 450 ms or > 470 ms (patients with bundle branch block) or PR interval outside the range of 115 to 220 ms, assessment may be repeated once for eligibility determination at Screening and/or on Day -
- •The patient has a supine systolic blood pressure < 90 or > 144 mm Hg or a supine diastolic blood pressure < 50 or > 94 mm Hg at Screening or on Day -
- •If out of range, assessment may be repeated once for eligibility determination at Screening and/or on Day -
- •The patient has a resting heart rate < 40 or > 90 bpm (not on ECGs) and considered clinically significant by the Investigator at Screening or on Day
- •If out of range, the assessment may be repeated once for eligibility determination at Screening and/or on Day -
- •The patient plans to use any other prohibited medication or undergo any prohibited procedure during the study. Oral antibiotics are permitted. Bleach baths are not permitted.
- •The patient has a risk of suicide on the Patient Health Questionnaire-2 (PH 2) or in the judgment of the Investigator, or the patient has made a suicide attempt or has a history of deliberate self-harm in the 6 months prior to Screening.
- •The patient is compulsorily detained for a medical or psychiatric illness.
- •The patient or their immediate family are personnel at the clinical site.
- •The patient is unable to comply with restrictions and prohibited activities/treatments as listed in the study protocol.
研究组 & 干预措施
300 mg
BSI-045B 300 mg SC QW × 4 weeks, then BSI-045B 300 mg SC Q2W through Week 24
干预措施: BSI-045B (Drug)
结局指标
主要结局
Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26
时间窗: Week 26
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.
Safety Profile of Study Treatment
时间窗: Day 1 to Week 36
Number of Participants With Treatment-emergent Adverse Events
次要结局
- Pharmacokinetic Parameters(Weeks 4, 24, and 26)
- Immunogenicity Following BSI-045B Treatment(Day 1 to Week 36)